Johnson & Johnson (US)

Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims

Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately $8 Billion NEW BRUNSWICK, N.J. – Sept. 20, 2024...

RYBREVANT ® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer

Approval based on compelling safety and efficacy from the Phase 3 MARIPOSA-2 study, marking the third new indication for RYBREVANT ® this year, with four indications overall RARITAN, New Jersey (September 19, 2024) – Johnson & Johnson (NYSE: JNJ)...

Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrence BARCELONA, September 16, 2024 – Johnson & Johnson (NYSE:JNJ) announced today...

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, September 15, 2024 – Johnson & Johnson...

Shockwave Medical Expands U.S. Peripheral IVL Portfolio with Enhanced Catheter

Shockwave E 8 Augments IVL’s Capabilities for Physicians Treating Peripheral Arterial Disease Above and Below the Knee SANTA CLARA, CA, September 16, 2024 – Shockwave Medical, Inc., part of Johnson & Johnson MedTech* and a global leader in the...

RYBREVANT ® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today...

RYBREVANT ® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR -mutated lung cancer

Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 3...

Medical technologies

TREMFYA ® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease

The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program 1,2,3,4,5 TREMFYA ® is now...

Johnson & Johnson Updates the Brand Identity of its MedTech Company Brands

Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS will now go by Johnson & Johnson MedTech The planned transition has no impact on the Company’s products New Brunswick, NJ – (09/10/2024) – Today, Johnson & Johnson shared that its...